• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

发现一种有效的、选择性的、细胞活性的 mA 去甲基化酶 ALKBH5 抑制剂。

Discovery of a potent, selective and cell active inhibitor of mA demethylase ALKBH5.

机构信息

Department of Medicinal Chemistry, School of Medicine, Nankai University, Tianjin, 300071, China; State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, and Collaborative Innovation Center for Biotherapy, Chengdu, Sichuan, 610041, China.

State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, and Collaborative Innovation Center for Biotherapy, Chengdu, Sichuan, 610041, China; School of Basic Medical Sciences and Forensic Medicine, North Sichuan Medical College, Nanchong, Sichuan, 637000, China.

出版信息

Eur J Med Chem. 2022 Aug 5;238:114446. doi: 10.1016/j.ejmech.2022.114446. Epub 2022 May 11.

DOI:10.1016/j.ejmech.2022.114446
PMID:35597008
Abstract

AlkB homolog 5 (ALKBH5) is an RNA mA demethylase involved in the regulation of genes transcription, translation and metabolism and has been considered as a promising therapeutic target for various human diseases, especially cancers. However, there is still a lack of potent and selective ALKBH5 inhibitors. Herein, we report a new class of ALKBH5 inhibitors containing the 1-aryl-1H-pyrazole scaffold, which were obtained through fluorescence polarization-based screening, structural optimization and structure-activity relationship analysis. Among these compounds, 20m was the most potent one, which showed an IC value of 0.021 μM in fluorescence polarization assay. Compound 20m exhibited high selectivity towards ALKBH5 versus FTO as well as other AlkB subfamily members, indicating good selectivity for ALKBH5. Cellular thermal shift assay (CETSA) analysis showed that 20m could efficiently stabilize ALKBH5 in HepG2 cells. Dot blot assay demonstrated that 20m could increase mA level in intact cells. Collectively, 20m is a potent, selective and cell active ALKBH5 inhibitor and could be used as a versatile chemical probe to explore the biological function of ALKBH5.

摘要

ALKBH5 同源物 5(ALKBH5)是一种 RNA mA 去甲基酶,参与基因转录、翻译和代谢的调控,已被认为是治疗各种人类疾病,特别是癌症的有前途的治疗靶点。然而,仍然缺乏有效的、选择性的 ALKBH5 抑制剂。在此,我们报告了一类包含 1-芳基-1H-吡唑骨架的新型 ALKBH5 抑制剂,这些抑制剂是通过基于荧光偏振的筛选、结构优化和构效关系分析获得的。在这些化合物中,20m 是最有效的一种,在荧光偏振测定中其 IC 值为 0.021 μM。化合物 20m 对 ALKBH5 具有高选择性,相对于 FTO 以及其他 AlkB 亚家族成员具有良好的选择性,表明对 ALKBH5 具有良好的选择性。细胞热转移分析(CETSA)分析表明,20m 能够在 HepG2 细胞中有效地稳定 ALKBH5。点印迹分析表明,20m 能够增加完整细胞中的 mA 水平。总之,20m 是一种有效、选择性和细胞活性的 ALKBH5 抑制剂,可作为一种通用的化学探针,用于探索 ALKBH5 的生物学功能。

相似文献

1
Discovery of a potent, selective and cell active inhibitor of mA demethylase ALKBH5.发现一种有效的、选择性的、细胞活性的 mA 去甲基化酶 ALKBH5 抑制剂。
Eur J Med Chem. 2022 Aug 5;238:114446. doi: 10.1016/j.ejmech.2022.114446. Epub 2022 May 11.
2
Distinct RNA demethylation pathways catalyzed by nonheme iron ALKBH5 and FTO enzymes enable regulation of formaldehyde release rates.非血红素铁 ALKBH5 和 FTO 酶催化的独特 RNA 去甲基化途径能够调节甲醛释放速率。
Proc Natl Acad Sci U S A. 2020 Oct 13;117(41):25284-25292. doi: 10.1073/pnas.2007349117. Epub 2020 Sep 28.
3
Discovery of Pyrazolo[1,5-]pyrimidine Derivative as a Novel and Selective ALKBH5 Inhibitor for the Treatment of AML.发现吡唑并[1,5-]嘧啶衍生物作为一种新型和选择性 ALKBH5 抑制剂用于治疗 AML。
J Med Chem. 2023 Dec 14;66(23):15944-15959. doi: 10.1021/acs.jmedchem.3c01374. Epub 2023 Nov 20.
4
Mechanisms of substrate recognition and N6-methyladenosine demethylation revealed by crystal structures of ALKBH5-RNA complexes.晶体结构揭示 ALKBH5-RNA 复合物的底物识别和 N6-甲基腺苷去甲基化机制。
Nucleic Acids Res. 2022 Apr 22;50(7):4148-4160. doi: 10.1093/nar/gkac195.
5
Discovery of two novel ALKBH5 selective inhibitors that exhibit uncompetitive or competitive type and suppress the growth activity of glioblastoma multiforme.发现两种新型 ALKBH5 选择性抑制剂,它们表现出非竞争性或竞争性类型,并抑制多形性胶质母细胞瘤的生长活性。
Chem Biol Drug Des. 2022 Jul;100(1):1-12. doi: 10.1111/cbdd.14051. Epub 2022 Apr 8.
6
m A demethylase ALKBH5 promotes proliferation of esophageal squamous cell carcinoma associated with poor prognosis.去甲基酶 ALKBH5 促进食管鳞状细胞癌的增殖,与预后不良相关。
Genes Cells. 2020 Aug;25(8):547-561. doi: 10.1111/gtc.12792. Epub 2020 Jul 1.
7
Development of formaldehyde dehydrogenase-coupled assay and antibody-based assays for ALKBH5 activity evaluation.甲醛脱氢酶偶联测定法和基于抗体的测定法的开发用于 ALKBH5 活性评估。
J Pharm Biomed Anal. 2019 Jan 5;162:9-15. doi: 10.1016/j.jpba.2018.09.018. Epub 2018 Sep 7.
8
The RNA Demethylases ALKBH5 and FTO Regulate the Translation of ATF4 mRNA in Sorafenib-Treated Hepatocarcinoma Cells.ALKBH5 和 FTO 等 RNA 去甲基化酶调控索拉非尼处理肝癌细胞中 ATF4 mRNA 的翻译。
Biomolecules. 2024 Aug 1;14(8):932. doi: 10.3390/biom14080932.
9
N(6)-Methyladenosine: a conformational marker that regulates the substrate specificity of human demethylases FTO and ALKBH5.N(6)-甲基腺苷:一种调节人类去甲基化酶FTO和ALKBH5底物特异性的构象标志物。
Sci Rep. 2016 May 9;6:25677. doi: 10.1038/srep25677.
10
Identification of Flavin Mononucleotide as a Cell-Active Artificial N -Methyladenosine RNA Demethylase.鉴定黄素单核苷酸为一种细胞活性的人工 N6-甲基腺苷 RNA 去甲基酶。
Angew Chem Int Ed Engl. 2019 Apr 1;58(15):5028-5032. doi: 10.1002/anie.201900901. Epub 2019 Mar 12.

引用本文的文献

1
mA-driven transcriptomic rewiring in tumor immune surveillance.毫安驱动的肿瘤免疫监视中的转录组重排
J Immunother Cancer. 2025 Sep 3;13(9):e012744. doi: 10.1136/jitc-2025-012744.
2
Small-molecule and peptide inhibitors of m6A regulators.m6A调控因子的小分子和肽类抑制剂
Front Oncol. 2025 Aug 1;15:1629864. doi: 10.3389/fonc.2025.1629864. eCollection 2025.
3
Mechanistic insights into the role of RNA demethylase ALKBH5 in malignant tumor therapy.RNA去甲基化酶ALKBH5在恶性肿瘤治疗中作用的机制性见解
J Transl Med. 2025 Aug 13;23(1):905. doi: 10.1186/s12967-025-06938-w.
4
M6A Demethylase ALKBH5 in Human Diseases: From Structure to Mechanisms.人类疾病中的m6A去甲基化酶ALKBH5:从结构到机制
Biomolecules. 2025 Jan 21;15(2):157. doi: 10.3390/biom15020157.
5
RNA modifications in cancer.癌症中的RNA修饰
MedComm (2020). 2025 Jan 10;6(1):e70042. doi: 10.1002/mco2.70042. eCollection 2025 Jan.
6
Epitranscriptomic RNA mA Modification in Cancer Therapy Resistance: Challenges and Unrealized Opportunities.癌症治疗耐药中的表观转录组RNA m⁶A修饰:挑战与未实现的机遇
Adv Sci (Weinh). 2024 Dec 11;12(4):e2403936. doi: 10.1002/advs.202403936.
7
Regulation and application of mA modification in tumor immunity.毫安(mA)修饰在肿瘤免疫中的调控与应用
Sci China Life Sci. 2025 Apr;68(4):974-993. doi: 10.1007/s11427-024-2648-0. Epub 2024 Dec 6.
8
Role of the mA demethylase ALKBH5 in gastrointestinal tract cancer (Review).mA 去甲基化酶 ALKBH5 在胃肠道肿瘤中的作用(综述)。
Int J Mol Med. 2025 Feb;55(2). doi: 10.3892/ijmm.2024.5463. Epub 2024 Nov 29.
9
Epigenetics-targeted drugs: current paradigms and future challenges.表观遗传学靶向药物:当前范例与未来挑战。
Signal Transduct Target Ther. 2024 Nov 26;9(1):332. doi: 10.1038/s41392-024-02039-0.
10
Decoding the epitranscriptome: a new frontier for cancer therapy and drug resistance.解析表观转录组:癌症治疗和耐药性的新前沿。
Cell Commun Signal. 2024 Oct 21;22(1):513. doi: 10.1186/s12964-024-01854-w.